NCT05605964: An ongoing trial by Myovant Sciences GmbH
This trial is ongoing. It must report results 3 years, 3 months from now.
Full data
Full entry on ClinicalTrials.gov | NCT05605964 |
---|---|
Title | Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV) |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Jan. 25, 2023 |
Completion date | Feb. 28, 2027 |
Required reporting date | Feb. 28, 2028, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |